At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Designing Optimal Prevention and Management of Postoperative Nausea and Emesis for Patients Undergoing Laparoscopic Sleeve Gastrectomy
In Brief
A Phase 4 clinical trial evaluating Aprepitant 80 mg Oral Capsule, scopolamine transdermal, and 11 other interventions for Post-operative Nausea and Vomiting and Laparoscopic Sleeve Gastrectomy. Completed, enrolled 83 participants across 1 site.
Detailed Summary
Bariatric surgery remains the most effective therapy for obesity. Postoperative nausea and vomiting (PONV) are commonly reported following bariatric surgery. The proposed study focuses on the most common bariatric procedure performed, laparoscopic sleeve gastrectomy (LSG), and aims to assess the effect of a post-operative nausea and vomiting-specific intervention. The investigators hypothesize that the intervention group will experience a reduction of nausea-related prolonged hospital stay and significantly improve patient-reported quality of recovery from surgery and quality of life.
Study Details
Timeline
Interventions
aprepitant 80 mg orally one hour prior to scheduled surgery
scopolamine transdermal patch one hour prior to scheduled surgery
Maintenance of anesthesia without the use of inhaled anesthetics.
Dexamethasone 8 mg intraoperatively
Ondansetron 4 mg intraoperatively. Ondansetron will be given twice. Once intraoperatively and then post- operatively.
Postoperatively scheduled Reglan
Postoperatively scheduled ondansetron
Postoperatively as needed compazine for breakthrough PONV
Reversal with sugammadex
Intravenous anesthesia will be maintained through IV propofol
maintenance of anesthesia in the intervention arm
intermittent bolus dosing of fentanyl will be used after induction for anesthesia maintenance
inhalational anesthesia
inhalational anesthesia